AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22576032 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CPB without cardiotomy suction
Number of subjects: 60
Study 22576032 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB with cardiotomy suction
Number of subjects: 60
Study 20032699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6, 1.2, 2.4 ng/ml)
Number of subjects: 11
Study 20032699 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1, 2, 4 microg/ml)
Number of subjects: 11
Study 18754983 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal warm packs
Number of subjects: 697
Study 18754983 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 697
Study 15957828 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Xuefu Capsule (PXC) with conventional western medicine
Number of subjects: 92
Study 15957828 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 92
Study 11989834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg
Number of subjects: 36
Study 11989834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 36
Study 11989834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9872814 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PGE2 (100 microgram)
Number of subjects: 8
Study 8650026 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Response (ABR)
Number of subjects: 60
Study 8650026 — intervention group
Group type: COMPARATOR
Intervention: Pure Tone Audiometry
Number of subjects: 60
Study 2169638 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (as a source of gamma-linolenic acid)
Number of subjects: 0
Study 7312535 — intervention group
Group type: EXPERIMENTAL
Intervention: Content presented aurally at an expanded rate of speech
Number of subjects: 60
Study 7312535 — intervention group
Group type: EXPERIMENTAL
Intervention: Content presented aurally at a normal rate of speech
Number of subjects: 60
Study 7312535 — intervention group
Group type: EXPERIMENTAL
Intervention: Content presented aurally at a compressed rate of speech
Number of subjects: 60
Study 7312535 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical content presented at variable rates
Number of subjects: 60
Study 7312535 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological content presented at variable rates
Number of subjects: 60
Study 31995813 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (single-dose, 200 mg)
Number of subjects: 0
Study 31283407 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid-style consolidation chemotherapy (ADE and MAE)
Number of subjects: 651
Study 31283407 — intervention group
Group type: COMPARATOR
Intervention: Lymphoid-style consolidation chemotherapy (IB)
Number of subjects: 651
Study 31283407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group with intention to undergo stem-cell transplantation (SCT)
Number of subjects: 651
Study 28214913 — intervention group
Group type: EXPERIMENTAL
Intervention: BNO 1016 (Sinupret extract)
Number of subjects: 929
Study 28214913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 929
Study 26552423 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological self-management modular program group intervention along with standard of care
Number of subjects: 206
Study 26552423 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment only
Number of subjects: 206
Study 24126178 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (30 g of milled flaxseed daily for 6 months)
Number of subjects: 110
Study 24126178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily ingestion of placebo for 6 months)
Number of subjects: 110
Study 21701431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 237
Study 21701431 — intervention group
Group type: COMPARATOR
Intervention: Endometrial Ablation (EA)
Number of subjects: 237
Study 19388862 — intervention group
Group type: EXPERIMENTAL
Intervention: Woolen underwear and woolen bedding (woolen bed liner, woolen quilt, and pillow) for 6 weeks
Number of subjects: 50
Study 19388862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what they received)
Number of subjects: 50
Study 17433313 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hCG (r-hCG)
Number of subjects: 284
Study 17433313 — intervention group
Group type: COMPARATOR
Intervention: Urinary hCG (u-hCG)
Number of subjects: 284
Study 15369762 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva from patients with diabetes mellitus
Number of subjects: 52
Study 15369762 — intervention group
Group type: COMPARATOR
Intervention: Saliva from healthy control subjects incubated with hypochloric acid
Number of subjects: 52
Study 15369762 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of advanced glycation endproducts in patients with diabetes mellitus
Number of subjects: 52
Study 12445026 — intervention group
Group type: EXPERIMENTAL
Intervention: V11294A (300 mg)
Number of subjects: 8
Study 12445026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10427934 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO/UNICEF 40-hour course 'Breastfeeding counselling: a training course'
Number of subjects: 60
Study 10427934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 8551488 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 46
Study 8551488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 1697284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 60
Study 1697284 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HAES)
Number of subjects: 60
Study 1697284 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 1697284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HA and HAES)
Number of subjects: 60
Study 7009887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 57
Study 7009887 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole combination
Number of subjects: 57
Study 30413516 — intervention group
Group type: EXPERIMENTAL
Intervention: ActWELL weight management intervention (diet, physical activity, behaviour change techniques)
Number of subjects: 414
Study 30413516 — intervention group
Group type: EXPERIMENTAL
Intervention: ActWELL weight management intervention
Number of subjects: 414
Study 27050206 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus chemotherapy (procarbazine, CCNU, and vincristine)
Number of subjects: 251
Study 27050206 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 251
Study 23688162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% nifedipine cream
Number of subjects: 20
Study 23688162 — intervention group
Group type: COMPARATOR
Intervention: Good moisturizer (control)
Number of subjects: 20
Study 22850710 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial (TT) group
Number of subjects: 76
Study 22850710 — intervention group
Group type: COMPARATOR
Intervention: Anteromedial (AM) group
Number of subjects: 76
Study 21173378 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by either surgery or chemoradiotherapy
Number of subjects: 47
Study 17368645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer solution
Number of subjects: 178
Study 17368645 — intervention group
Group type: COMPARATOR
Intervention: Glucose-boosted saline solution (5% glucose)
Number of subjects: 178
Study 16379581 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil (CP-101,606) 72-hour infusion
Number of subjects: 404
Study 16379581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 11917251 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 1% aqueous extract of Fucus vesiculosus, applied twice daily for five weeks
Number of subjects: 0
Study 11917251 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9637644 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg oral clonidine (clonidine group, n=25)
Number of subjects: 50
Study 9637644 — intervention group
Group type: COMPARATOR
Intervention: No clonidine (control group, n=25)
Number of subjects: 50
Study 7527329 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 0
Study 2604057 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation
Number of subjects: 30
Study 2604057 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 28421779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.5 g/kg/day)
Number of subjects: 28
Study 28421779 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin)
Number of subjects: 28
Study 26329749 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day for 5 years
Number of subjects: 57
Study 26329749 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine after lamivudine 100 mg/day for 2 years
Number of subjects: 57
Study 26329749 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment
Number of subjects: 57
Study 23159787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic music cueing
Number of subjects: 30
Study 23159787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome cueing
Number of subjects: 30
Study 23159787 — intervention group
Group type: COMPARATOR
Intervention: Uncued baseline
Number of subjects: 30
Study 23159787 — intervention group
Group type: COMPARATOR
Intervention: Retest measures
Number of subjects: 30
Study 21545506 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cyclosporin emulsion once daily (group A)
Number of subjects: 40
Study 21545506 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cyclosporin emulsion twice daily (group B)
Number of subjects: 40
Study 21545506 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study 21545506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study 18840643 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake (670-2003 mg/d)
Number of subjects: 31
Study 18840643 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I concentration
Number of subjects: 31
Study 18840643 — intervention group
Group type: EXPERIMENTAL
Intervention: Other serum hormone levels
Number of subjects: 31
Study 18840643 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of bone metabolism, habitual physical activity, habitual calcium intake, and physical fitness
Number of subjects: 31
Study 16553019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg
Number of subjects: 207
Study 16553019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 6 mg
Number of subjects: 207
Study 16553019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 207
Study 16553019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 2 mg
Number of subjects: 207
Study 16553019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 15071278 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian route of insertion
Number of subjects: 539
Study 11128236 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 47
Study 11128236 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 47
Study 11128236 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 47
Study 11128236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9188109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg.kg‐1 nasally
Number of subjects: 47
Study 9188109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 rectally
Number of subjects: 47
Study 9188109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg.kg‐1 sublingually
Number of subjects: 47
Study 9188109 — intervention group
Group type: COMPARATOR
Intervention: All groups (nasal, rectal, sublingual)
Number of subjects: 47
Study 8430625 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study 8430625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 2964215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.05-0.15 μg/kg)
Number of subjects: 10
Study 2964215 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.05-0.15 mg/kg)
Number of subjects: 10
Study 2964215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 10
Study 2964215 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 10
Study 29846992 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Adverse Electrical Remodeling (AER) measured by SAI QRST
Number of subjects: 961
Study 29846992 — intervention group
Group type: COMPARATOR
Intervention: High SAI QRST (T3)
Number of subjects: 961
Study 29846992 — intervention group
Group type: COMPARATOR
Intervention: Medium SAI QRST (T2)
Number of subjects: 961
Study 26784973 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 1.5 g daily for 6 months
Number of subjects: 28
Study 26784973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26784973 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 28
Study 25819604 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (offered two selected vegetables)
Number of subjects: 70
Study 25819604 — intervention group
Group type: COMPARATOR
Intervention: No-choice group (offered one vegetable)
Number of subjects: 70
Study 23731362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200-mg oral-N-acetylcysteine (NAC) two times a day, starting 48 hours before and up to 72 hours after surgery
Number of subjects: 240
Study 23731362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 23731362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200-mg oral-N-acetylcysteine (NAC)
Number of subjects: 240
Study 21986350 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education
Number of subjects: 623
Study 21986350 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 623
Study 21986350 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 623
Study 19995505 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma
Number of subjects: 31
Study 19995505 — intervention group
Group type: COMPARATOR
Intervention: Delton FS(+)
Number of subjects: 31
Study 17011327 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg every 4 weeks (group 1)
Number of subjects: 62
Study 17011327 — intervention group
Group type: EXPERIMENTAL
Intervention: Not treated (group 2)
Number of subjects: 62
Study 17011327 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched normal volunteers)
Number of subjects: 62
Study 15233305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (O)
Number of subjects: 12
Study 15233305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (R)
Number of subjects: 12
Study 15233305 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (H)
Number of subjects: 12
Study 15233305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Number of subjects: 12
Study 15233305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of drugs (O, R, H, Z)
Number of subjects: 12
Study 11198725 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg
Number of subjects: 301
Study 11198725 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 12.5 mg
Number of subjects: 301
Study 11198725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (demulcent lozenge without active drug)
Number of subjects: 301
Study 9141578 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler velocimetry
Number of subjects: 11375
Study 8363681 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg initial dose, repeat 100-200 mg at 2 hours)
Number of subjects: 20
Study 8363681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg bite and swallow every hour up to 20 mg total)
Number of subjects: 20
Study 3540024 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1-week course)
Number of subjects: 20
Study 3540024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30020962 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing for expanded carrier screening reporting carrier results for 728 gene/condition pairs and results for 121 secondary findings.
Number of subjects: 277
Study 27262966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociated pulmonary vein activity after PVI
Number of subjects: 52
Study 27262966 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 52
Study 27262966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing within the isolated PV
Number of subjects: 52
Study 27262966 — intervention group
Group type: COMPARATOR
Intervention: Presence of AF prior to achieving PVI
Number of subjects: 52
Study 24844271 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily for 24 weeks
Number of subjects: 240
Study 24844271 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 24 weeks
Number of subjects: 240
Study 23263426 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace
Number of subjects: 17
Study 23263426 — intervention group
Group type: COMPARATOR
Intervention: Delton FS+
Number of subjects: 17
Study 20122848 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU vitamin D per week (group DD)
Number of subjects: 437
Study 20122848 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D per week (group DP)
Number of subjects: 437
Study 20122848 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group PP)
Number of subjects: 437
Study 18402717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine purite 0.1% TID
Number of subjects: 40
Study 18402717 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1% TID
Number of subjects: 40
Study 16377943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand
Number of subjects: 30
Study 16377943 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant hand
Number of subjects: 30
Study 16377943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hands
Number of subjects: 30
Study 12569373 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 + cisplatin (CPT-P)
Number of subjects: 398
Study 12569373 — intervention group
Group type: COMPARATOR
Intervention: cisplatin + vindesine (VDS-P)
Number of subjects: 398
Study 12569373 — intervention group
Group type: COMPARATOR
Intervention: CPT-11 alone (CPT)
Number of subjects: 398
Study 10655908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (2.5 micrograms kg‐1 min‐1)
Number of subjects: 30
Study 10655908 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 10655908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Saline)
Number of subjects: 30
Study 8542050 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril/hydrochlorothiazide, 20/25 mg
Number of subjects: 334
Study 8542050 — intervention group
Group type: COMPARATOR
Intervention: benazepril, 20 mg
Number of subjects: 334
Study 8542050 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide, 25 mg
Number of subjects: 334
Study 8542050 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 334
Study 8263299 — intervention group
Group type: EXPERIMENTAL
Intervention: T.O.M. ointment containing oestradiol; applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Number of subjects: 80
Study 8263299 — intervention group
Group type: COMPARATOR
Intervention: Ointment without oestradiol (non-treated group); applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Number of subjects: 80
Study 3986167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 200 mg of progesterone
Number of subjects: 50
Study 3986167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 400 mg of progesterone
Number of subjects: 50
Study 3986167 — intervention group
Group type: COMPARATOR
Intervention: Vaginal administration of 400 mg of progesterone (compared to placebo)
Number of subjects: 50
Study 31899564 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling + Nicotine Replacement Therapy (C + NRT)
Number of subjects: 278
Study 31899564 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (C)
Number of subjects: 278
Study 30115484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil PCA (40 μg bolus on demand with a 2 min lockout)
Number of subjects: 401
Study 30115484 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (100 mg every 4 h, up to 400 mg in 24 h)
Number of subjects: 401
Study 27537587 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol/remifentanil/DEX with loading dose (PRDw)
Number of subjects: 86
Study 27537587 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol/remifentanil/DEX without loading dose (PRDo)
Number of subjects: 86
Study 27537587 — intervention group
Group type: COMPARATOR
Intervention: propofol/remifentanil/Ringer solution (PRR)
Number of subjects: 86
Study 24683594 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC+intermediate adhesive resin+PFC
Number of subjects: 30
Study 24683594 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC+PFC
Number of subjects: 30
Study 24683594 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC+flowable resin+PFC
Number of subjects: 30
Study 22710250 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (RM)
Number of subjects: 29
Study 22710250 — intervention group
Group type: COMPARATOR
Intervention: No recruitment maneuver (no-RM)
Number of subjects: 29
Study 20434110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg atracurium
Number of subjects: 79